United States· US:0562-7805_7ccbaf67-ab6a-490a-9b63-598d75a7afca
RhoGAM Ultra-Filtered PLUS
A medicinal product containing human rho(d) immune globulin, registered in United States by Kedrion Biopharma Inc.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- HUMAN RHO(D) IMMUNE GLOBULIN
- Manufacturer
- Kedrion Biopharma Inc
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc1105627805011 POUCH in 1 CARTON (0562-7805-01) / 1 INJECTION, SOLUTION in 1 POUCH (0562-7805-00)
- ndc1105627805055 POUCH in 1 CARTON (0562-7805-05) / 1 INJECTION, SOLUTION in 1 POUCH (0562-7805-00)
- ndc11056278052525 POUCH in 1 CARTON (0562-7805-25) / 1 INJECTION, SOLUTION in 1 POUCH (0562-7805-00)
- ndc110562-7805-01
- ndc110562-7805-05
- ndc110562-7805-25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Human rho(d) immune globulin in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAnti-D (RHO) immunoglobulin 1,250units/1ml solution for injection pre-filled syringesBaxter Healthcare Ltd
- FinlandRhesonativOctapharma Ab
- BelgiumImmunorho 300 µg/2 mlKedrion
- NetherlandsRhesonativ 625 IE/ml, oplossing voor injectieOctapharma GmbH
- PolandGamma anty-D 150Synthaverse S.A.
- SwedenRhesonativ 625 IE/ml Injektionsvätska, lösningOctapharma AB
- CzechiaIGAMADInstituto Grifols, S.A., Barcelona
- ItalyIGAMAD*1 fiala IM 1.500 UI + 1 fiala solv 2 mlINSTITUTO GRIFOLS S.A.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Rhesonativ, Rhophylac
- Belgium · Immunorho, Rhophylac
- Bulgaria · Резонатив
- Cyprus · Rhesonativ, Rhophylac
- Czechia · Igamad, Rhesonativ
- Germany · Rhesonativ, Rhophylac
- Denmark · Rhesonativ, Rhophylac
- Estonia · Rhesonativ
- Spain · Igamad, Rhophylac
- Finland · Rhophylac
- France · Rhesonativ, Rhophylac
- United Kingdom (Northern Ireland) · D-Gam, Rhophylac
- Greece · Rhophylac
- Hungary · Rhesonativ, Rhophylac
- Ireland · Rhophylac
- Iceland · Rhesonativ, Rhophylac
- Italy · Igamad, Immunorho
- Lithuania · Rhesonativ
- Luxembourg · Rhesonativ, Rhophylac
- Latvia · Rhesonativ
- Malta · Rhesonativ, Rhophylac
- Netherlands · Rhesonativ, Rhophylac
- Norway · Rhesonativ, Rhophylac
- Poland · Gamma Anty-D, Rhesonativ
- Portugal · Rhesonativ, Rhophylac
- Romania · Rhesonativ, Rhophylac
- Sweden · Rhesonativ, Rhophylac
- Slovenia · Rhesonativ, Rhophylac
- Slovakia · Igamad, Rhesonativ
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5122821e-5b80-49e0-8f82-bc796f7c86fb GET /v1/drugs/5122821e-5b80-49e0-8f82-bc796f7c86fb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAMUSCULAR",
"source": "ndc",
"strength": "300",
"substance": "HUMAN RHO(D) IMMUNE GLOBULIN",
"productndc": "0562-7805",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "ug/1",
"application_number": "BLA103777",
"marketing_category": "BLA"
}See everything about human rho(d) immune globulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.